Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM-BA-9 is an investigational chimeric antigen receptor macrophage (CAR-M) cell therapy targeting carbonic anhydrase IX (CA9). Developed by Liangyou Gu, it is designed for the treatment of unresectable or metastatic clear cell renal cell carcinoma (ccRCC). CA9 is a cell-surface protein highly overexpressed in ccRCC. CM-BA-9 consists of autologous or donor-derived macrophages genetically engineered to express a CAR targeting CA9, which enables them to specifically recognize and phagocytose CA9-expressing tumor cells, secrete pro-inflammatory cytokines, and remodel the immunosuppressive tumor microenvironment. It is administered via intratumoral injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CM-BA-9.